Author: Benoni, Roberto; Krafcikova, Petra; Baranowski, Marek R.; Kowalska, Joanna; Boura, Evzen; Cahová, Hana
Title: Substrate Specificity of SARS-CoV-2 Nsp10-Nsp16 Methyltransferase Cord-id: bmipb3fm Document date: 2021_8_30
ID: bmipb3fm
Snippet: The ongoing COVID-19 pandemic exemplifies the general need to better understand viral infections. The positive single-strand RNA genome of its causative agent, the SARS coronavirus 2 (SARS-CoV-2), encodes all viral enzymes. In this work, we focused on one particular methyltransferase (MTase), nsp16, which, in complex with nsp10, is capable of methylating the first nucleotide of a capped RNA strand at the 2′-O position. This process is part of a viral capping system and is crucial for viral eva
Document: The ongoing COVID-19 pandemic exemplifies the general need to better understand viral infections. The positive single-strand RNA genome of its causative agent, the SARS coronavirus 2 (SARS-CoV-2), encodes all viral enzymes. In this work, we focused on one particular methyltransferase (MTase), nsp16, which, in complex with nsp10, is capable of methylating the first nucleotide of a capped RNA strand at the 2′-O position. This process is part of a viral capping system and is crucial for viral evasion of the innate immune reaction. In light of recently discovered non-canonical RNA caps, we tested various dinucleoside polyphosphate-capped RNAs as substrates for nsp10-nsp16 MTase. We developed an LC-MS-based method and discovered four types of capped RNA (m(7)Gp(3)A(G)- and Gp(3)A(G)-RNA) that are substrates of the nsp10-nsp16 MTase. Our technique is an alternative to the classical isotope labelling approach for the measurement of 2′-O-MTase activity. Further, we determined the IC(50) value of sinefungin to illustrate the use of our approach for inhibitor screening. In the future, this approach may be an alternative technique to the radioactive labelling method for screening inhibitors of any type of 2′-O-MTase.
Search related documents:
Co phrase search for related documents- accessory structural protein and acute respiratory syndrome: 1, 2, 3, 4, 5
- acetate buffer and acute respiratory syndrome: 1
- acetate buffer and lysis buffer: 1, 2
- acid inducible and activation factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acid inducible and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acid inducible gene and activation factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acid inducible gene and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- activation factor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
- acute respiratory syndrome and additional layer: 1, 2, 3, 4, 5
- acute respiratory syndrome and additional treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- acute respiratory syndrome and adenine dinucleotide: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and lysis buffer: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date